<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:mp ids='MP_0005039'>Hypoxia</z:mp> is a biochemical condition where reduced oxygen partial pressure at tissue level occurs </plain></SENT>
<SENT sid="1" pm="."><plain>This metabolic situation can lead to resistance to radio and chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumours</z:e>, <z:mp ids='MP_0005039'>hypoxia</z:mp> is a common characteristic, having a great impact at biological level, being of tremendous importance for complete understanding of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVES: We studied the behavior of 99mTc-HL91 in vivo, using an animal model based on Balb-c nu/nu mice with a xenotransplant of the human colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell line, WiDr </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIAL AND METHODS: In vivo studies using an animal model of xenograft on Balb/c nu/nu <z:mp ids='MP_0003815'>nude</z:mp> mice were carried out </plain></SENT>
<SENT sid="5" pm="."><plain>This model, allowed us to evaluate the radiopharmaceutical biodistribution and to calculate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>/muscle ratio, acquired after 99mTc-HL91 injection </plain></SENT>
<SENT sid="6" pm="."><plain>We also performed ex vivo studies, using the excised <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> to access viability and to characterize the intracellular production of reactive oxygen species and the status of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential through flow cytometry </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS AND DISCUSSION: The biodistribution after 99mTc-HL91 injection showed urinary and hepatobilliary excretion in similar proportions and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> uptake around 4.4% of administered activity </plain></SENT>
<SENT sid="8" pm="."><plain>This uptake was higher at the bigger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Through flow cytometry we observed that larger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> have a higher amount of reactive oxygen species and a decrease in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: 99mTc-HL91 allowed a non-invasive evaluation of the <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> oxidative state by nuclear medicine functional imaging </plain></SENT>
<SENT sid="11" pm="."><plain>This information can be of high importance at the pre-treatment estimation of this type of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
</text></document>